Injuries & Orthopedics
Peptides for Muscle Tears & Strains: The Recovery Evidence
A clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
BPC-157TB-500 / Thymosin beta-4MGFPEG-MGFGrade C evidence
The quick verdict
Muscle is the most biologically plausible target for repair peptides, yet no completed randomized human trial proves any of them heals a tear or strain. Here is the honest, evidence-graded ranking for 2026.
- Best overall
- BPC-157 — The broadest, most directly muscle-relevant animal data — transected quadriceps, myotendinous junction, muscle crush, muscle-to-bone reattachment — plus a human safety pilot and the field's only registered muscle-strain RCT. Still Grade C, but the best-studied for muscle.
- Best value
- TB-500 / Thymosin beta-4 — A genuinely muscle-specific mechanism — injury-induced chemoattraction of satellite-cell-derived myoblasts, plus identification as an exercise exerkine — gives it real rationale, though it has no human muscle data and the TB-500 fragment is thinner than native Tbeta4.
- Best for A well-vascularized Grade I-II muscle strain being managed with rehab
- BPC-157 — Muscle heals on its own through satellite cells, and the BPC-157 animal models used transected and crushed muscle that retains repair capacity, so any plausible adjunct role concentrates here — never for a full rupture needing surgical reattachment.
How we evaluated
We ranked peptides by the strength of evidence for muscle injury specifically — hamstring, calf and quad strains, muscle tears and myotendinous injury — not by marketing popularity or general tissue-repair reputation. Human trial evidence outweighs animal data, which outweighs mechanism and anecdote. Every claim is graded A-D, human evidence is held separate from preclinical and in-vitro work, and precise recovery-percentage marketing without a traceable primary source is treated as unsupported. This is an editorial review of the literature, not medical advice or a sourcing guide.
- Muscle-specific human evidence. Completed randomized, placebo-controlled trials in a muscle-strain or muscle-tear population carry the most weight. As of 2026, none has reported; one BPC-157 hamstring-strain RCT is registered but not yet reporting.
- Muscle-specific preclinical evidence. Dedicated animal muscle models (transected quadriceps, muscle crush, myotendinous junction) count far more than general tissue or wound-healing data extrapolated to muscle.
- Mechanistic plausibility for the target tissue. Satellite-cell and myoblast recruitment, angiogenesis and inflammation modulation matter most in well-vascularized, regenerative skeletal muscle — but a contested mechanism is graded down.
- Safety, legality and honesty of claims. Regulatory status, anti-doping prohibition, mechanism-based oncologic caution, contamination risk of unregulated product, and whether marketed claims match the actual data.
Rating scale: 1-5 stars, reflecting strength of muscle-specific evidence. No peptide here exceeds preclinical (Grade C) support, so none earns a top score.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | BPC-157 | C | 3.0 | A well-vascularized Grade I-II muscle strain being managed with load control and rehab — as a plausible adjunct only, never for a full rupture needing reattachment | Varies by pharmacy (gray-zone) |
| 2 | TB-500 / Thymosin beta-4 | C | 2.5 | Readers comparing muscle-specific mechanism honestly — Tbeta4 has real preclinical muscle rationale but no human muscle proof and a fragment-versus-native ambiguity | Varies (gray-zone) |
| 3 | MGF (Mechano Growth Factor / IGF-1Ec) | C | 1.5 | Understanding why the most heavily marketed satellite-cell peptide is graded down — a mechanism with real doubt and no human evidence | Varies (research-use-only) |
| 4 | PEG-MGF | D | 1.0 | Understanding why a pegylated MGF derivative does not automatically inherit muscle evidence — a caution case, not a recommendation | Varies (research-use-only) |
BPC-157
Best-studied for muscle — but still preclinical-dominant
BPC-157 is a synthetic stable gastric pentadecapeptide (sequence GEPPPGKPADDAGLV) and the single best-evidenced candidate for muscle injury — which in 2026 still means preclinical-dominant. Its muscle record is the most directly relevant in this class: in rats with a completely transected quadriceps, a defect that does not heal spontaneously, BPC-157 consistently improved muscle healing and functional restoration across a 72-day period. It healed the myotendinous junction after quadriceps-tendon dissection, improving failure load from the earliest intervals, and restored muscle-to-bone reattachment after surgical detachment with consistent recovery on macroscopic, ultrasound, MRI, biomechanical and functional assessments. In muscle crush injury it improved healing and, importantly, counteracted corticosteroid-induced impairment. A 2025 systematic review of orthopedic-sports applications found the literature dominated by animal work on the order of roughly 35 preclinical studies to 1 clinical. The human side is where it thins out: total published human exposure is dozens of subjects in uncontrolled settings, most concretely a 2025 IV safety pilot in two adults that showed no adverse effects and no biomarker changes — a safety signal only, not efficacy. Crucially for this condition, BPC-157 is the subject of the field's first registered efficacy RCT, a Phase 2, double-blind, placebo-controlled trial of subcutaneous BPC-157 for acute grade-II hamstring strain, with MRI-assessed injury volume and return to sport as co-primary endpoints. Until it reports, the honest grade is C.
Strengths
- The broadest and most directly muscle-relevant animal record in the class — transected quadriceps, myotendinous junction, muscle crush, and muscle-to-bone reattachment
- Counteracted corticosteroid-impaired muscle healing and is backed by a coherent VEGFR2-driven angiogenesis mechanism fitting a well-vascularized strain
- The only peptide here with the field's first registered muscle-strain RCT plus a small human safety pilot showing no biomarker harm
Weaknesses
- No completed randomized, placebo-controlled human trial for muscle injury; the registered hamstring RCT has not yet reported
- Cannot reattach a fully ruptured muscle that needs surgical repair — the animal data are on partial and surgically controlled injuries
- Unapproved drug in a 2026 regulatory gray zone; WADA S0 and DoD prohibited; unregulated research-chemical product carries contamination and dosing-accuracy risk
- Best for
- A well-vascularized Grade I-II muscle strain being managed with load control and rehab — as a plausible adjunct only, never for a full rupture needing reattachment
- Pricing
- Varies by pharmacy (gray-zone)
Source: BPC 157 muscle-to-bone reattachment in rats, 2025 (PMC11768438)
TB-500 / Thymosin beta-4
A genuine muscle mechanism, but no human muscle data
Thymosin beta-4 (Tbeta4) is a naturally occurring 43-amino-acid actin-binding protein; TB-500 is the synthetic N-acetylated heptapeptide fragment (Ac-LKKTETQ) reproducing its principal actin-binding and cell-migration motif — related but not identical, a distinction routinely blurred in marketing. Its muscle case is genuinely mechanism-forward and the reason it outranks MGF. After muscle injury, local Tbeta4 production rises and chemoattracts satellite-cell-derived myoblasts and myocytes to the injury site, a directly muscle-specific repair role, and it was later identified as the most upregulated secreted protein in the exercise-induced muscle secretome — a true exerkine — while nudging the differentiation marker myogenin in C2C12 myoblasts. Mechanistically it sequesters monomeric G-actin to power directed cell migration and signals through ILK/PINCH/Akt for cell survival. The weakness is everything downstream of the mechanism. A 2026 scoping review mapping Tbeta4 and TB-500 across tissue repair found the literature weighted toward in-vitro and animal designs, that most studies evaluated full-length Tbeta4 rather than the marketed TB-500 fragment, and that direct musculoskeletal categories were comparatively sparse, with direct TB-500 evidence limited to a single included study. The only human RCT data belong to full-length Tbeta4 in eye and skin indications, not muscle, and even there results were mixed, with the ophthalmic SEER-1 trial missing its primary endpoint. There is no human muscle-strain trial of either compound, so athletic use is anecdotal and often confounded by stacking with BPC-157.
Strengths
- A genuinely muscle-specific mechanism — injury-induced Tbeta4 chemoattracts satellite-cell-derived myoblasts to the damage site
- Identified as the most upregulated secreted protein in the exercise-induced muscle secretome, a real exerkine, with a clear actin-binding, pro-migration and pro-angiogenesis pathway
- A body of consistent in-vitro and animal muscle-mechanism data supporting a plausible repair role
Weaknesses
- Zero human muscle data — the only human RCT evidence is for full-length Tbeta4 in eye and skin, and it was mixed
- Most evidence is for native Tbeta4, not the marketed TB-500 fragment, whose direct musculoskeletal data is a single included study
- A real mechanism-based tumor-angiogenesis flag (Tbeta4 increased melanoma migration, tumor vessel number and lung metastases in a pivotal study); WADA S2.3 prohibited
- Best for
- Readers comparing muscle-specific mechanism honestly — Tbeta4 has real preclinical muscle rationale but no human muscle proof and a fragment-versus-native ambiguity
- Pricing
- Varies (gray-zone)
Source: Tokura et al., J Biochem 2011 (muscle injury Tbeta4 chemoattraction, PMID 20880960)
MGF (Mechano Growth Factor / IGF-1Ec)
The marketed satellite-cell peptide, with a contested mechanism
MGF, or Mechano Growth Factor, is the locally expressed, mechanosensitive splice variant of IGF-1 (IGF-1Ec in humans), sold as the synthetic 24-amino-acid C-terminal E-domain peptide. It is marketed precisely as the satellite-cell activator: the canonical model holds that mechanical load triggers rapid splicing toward MGF, whose E-peptide activates quiescent satellite cells and drives myoblast proliferation while suppressing premature differentiation, before mature IGF-1 takes over hypertrophy. Supporting muscle data exist — after cardiotoxin injury in mice, MGF expression rose early, preceding IGF-1Ea, and MGF overexpression modulated inflammatory cytokines and macrophage resolution — and Goldspink-lab rodent work reported faster fiber cross-sectional-area gains than IGF-1Ea. Despite the compelling narrative, MGF ranks third because three facts dominate. First, the signature mechanism is contested: a well-controlled pharmaceutical study found the synthetic MGF peptide had no effect on myoblasts or primary muscle stem cells up to 500 nanograms per milliliter, failing to increase proliferation or inhibit differentiation, while mature IGF-1 worked as expected, and a peer review judged the in-vivo evidence that a free MGF peptide even exists inadequate. Second, there are zero human trials of any kind. Third, native MGF's half-life is only about five to seven minutes, forcing local injection. Muscle recovery and hypertrophy claims in humans are therefore Grade D and anecdotal, confounded by polypharmacy. The headline safety concern is oncologic: the MGF E-peptide is pro-proliferative and anti-apoptotic and promoted osteosarcoma cell proliferation, migration and invasion in vitro.
Strengths
- A mechanistically compelling story tied to satellite-cell activation, with early-rising MGF expression after muscle injury in a mouse model
- Animal data showing modulation of inflammatory cytokines and macrophage resolution, plus reported faster fiber cross-sectional-area gains than IGF-1Ea
- Directly targets the muscle-specific regenerative lever (satellite cells) that partial-strain healing depends on
Weaknesses
- Its signature satellite-cell mechanism is contested — a controlled study found no effect on myoblasts or muscle stem cells, and a free MGF peptide's in-vivo existence was formally questioned
- Zero human trials of any kind, and a near-useless native half-life of minutes that forces local injection
- Mechanism-based oncologic risk (pro-proliferative E-peptide promoted osteosarcoma cell invasion in vitro); WADA names MGFs explicitly as prohibited
- Best for
- Understanding why the most heavily marketed satellite-cell peptide is graded down — a mechanism with real doubt and no human evidence
- Pricing
- Varies (research-use-only)
PEG-MGF
A pharmacokinetic fix with no independent efficacy data
PEG-MGF is the MGF E-domain peptide conjugated to polyethylene glycol to overcome native MGF's near-useless minutes-long half-life, enabling systemic subcutaneous dosing that community guides commonly cite around 100 to 400 micrograms two to three times weekly. On the evidence for muscle injury specifically, it is the weakest option in this review. PEG-MGF has no human trials and no independent muscle-repair efficacy data of its own — it borrows MGF's already-contested satellite-cell narrative and adds an engineering fix, not new proof. Its highest defensible grade is C for the inherited preclinical muscle signal and D for the marketed systemic-recovery claims, and here it is placed at Grade D because none of the muscle evidence is its own. It carries the same mechanism-based oncologic theoretical risk as MGF, since the E-peptide is pro-proliferative, pro-angiogenic and anti-apoptotic in cancer cell lines, plus a PEG-specific concern: repeated dosing can trigger anti-PEG antibody formation, which may accelerate clearance or cause hypersensitivity reactions. Regulatorily it also sits in a later FDA review batch than the others, deferred to a Pharmacy Compounding Advisory Committee meeting around February 2027, and removal from Category 2 does not authorize compounding. Treating PEG-MGF as an evidence-backed upgrade over MGF or the better-studied repair peptides for a muscle strain is a marketing position built on a pharmacokinetic tweak, not a research finding, and it inherits every unresolved doubt of the parent compound while adding one of its own.
Strengths
- Solves native MGF's minutes-long half-life problem with pegylation, enabling practical systemic subcutaneous dosing
- Shares MGF's satellite-cell-targeting rationale in principle, so any inherited preclinical signal is at least mechanistically relevant
- Widely available through research-chemical channels, making it easy to find in the current market
Weaknesses
- No human trials and no independent muscle-repair efficacy data of its own — every muscle claim is borrowed from contested MGF biology
- Adds a PEG-specific risk (anti-PEG antibody formation, accelerated clearance or hypersensitivity) on top of MGF's oncologic theoretical concern
- Unapproved and WADA S2.3 prohibited; sits in a later FDA review batch (deferred to ~February 2027), and removal from Category 2 does not authorize compounding
- Best for
- Understanding why a pegylated MGF derivative does not automatically inherit muscle evidence — a caution case, not a recommendation
- Pricing
- Varies (research-use-only)
Source: FDA Law Blog, 2026 (PEG-MGF in later PCAC batch, regulatory context)
Feature comparison
| Feature | BPC-157 | TB-500 / Thymosin beta-4 | MGF (Mechano Growth Factor / IGF-1Ec) | PEG-MGF |
|---|---|---|---|---|
| Dedicated animal muscle study | — | — | — | — |
| Muscle-specific mechanism | — | — | — | — |
| Human muscle trial (any) | — | — | — | — |
| Independent research groups | — | — | — | — |
| Feature | BPC-157 | TB-500 / Thymosin beta-4 | MGF (Mechano Growth Factor / IGF-1Ec) | PEG-MGF |
|---|---|---|---|---|
| FDA-approved for muscle use | — | — | — | — |
| WADA-prohibited | — | — | — | — |
| Mechanism-based oncologic caution | — | — | — | — |
| Honest marketing vs claims | — | — | — | — |
Frequently asked
Which peptide has the best evidence for a muscle tear or strain?
BPC-157, but only relatively. It has the broadest, most directly muscle-relevant animal data — transected quadriceps, myotendinous junction, muscle crush, and muscle-to-bone reattachment — plus a small human safety pilot and, uniquely, the field's only registered muscle-strain randomized trial (NCT07437547, a Phase 2 study in acute hamstring strain). That still makes it Grade C, not a proven therapy, because no controlled human trial has yet reported. TB-500 and thymosin beta-4 rank second on a genuine muscle mechanism but have zero human muscle data, and MGF and PEG-MGF sit lowest because their signature satellite-cell mechanism is actively contested.
Isn't MGF or PEG-MGF the satellite-cell peptide, so shouldn't it be first for rebuilding muscle?
It is the most heavily marketed as such, but the evidence is weaker than the pitch. MGF's headline satellite-cell-activation mechanism was contradicted by a well-controlled pharmaceutical study showing the synthetic peptide had no effect on myoblasts or primary muscle stem cells up to 500 nanograms per milliliter, while mature IGF-1 worked as expected. A peer review even questioned whether a free MGF peptide exists in the body at all, there are no human trials of any kind, and native MGF's half-life is only about five to seven minutes. PEG-MGF is an engineering fix for that half-life with no independent efficacy data of its own. Honest grade: C for mechanism, D for human recovery claims.
Why does TB-500 rank above MGF if neither has human muscle trials?
Because thymosin beta-4's muscle role is more robustly demonstrated preclinically. After muscle injury, local thymosin beta-4 production rises and chemoattracts satellite-cell-derived myoblasts to the damage site, a directly muscle-specific repair action, and it was later identified as the most upregulated secreted protein in the exercise-induced muscle secretome. MGF's core muscle mechanism, by contrast, is actively contested by a controlled null study. Both peptides are still Grade C and unproven in humans, most of the thymosin data are on full-length Tbeta4 rather than the TB-500 fragment people actually buy, and TB-500 carries a real tumor-angiogenesis safety flag. So TB-500 ranks second on stronger preclinical rationale, not on human proof.
Can any of these peptides replace surgery for a complete muscle rupture?
No evidence supports that. Skeletal muscle is well-vascularized and genuinely regenerative through its satellite cells, which is exactly why partial strains often heal well, but the animal data behind these peptides are on partial injuries and surgically controlled models. A complete rupture that needs reattachment is a structural problem, and none of these peptides has been shown in humans to reattach fully torn muscle. Framing any of them as a way to skip a needed surgical repair is unsupported by the literature. For a full-thickness tear, the decision belongs with an orthopedic surgeon, and a signaling peptide is not a substitute for structural repair.
Are these peptides legal, and will they make me fail a drug test?
They are unapproved drugs sitting in a 2026 regulatory gray zone after the FDA's compounding changes, and none is approved for any muscle indication. BPC-157 and TB-500 are scheduled for a Pharmacy Compounding Advisory Committee review on July 23, 2026, while PEG-MGF is deferred to a later batch around February 2027. For anyone subject to testing the answer is unambiguous: all four are prohibited at all times under WADA, BPC-157 under Class S0 and TB-500, MGF and PEG-MGF under S2.3, with TB-500 and MGF named explicitly. BPC-157 is also on the U.S. Department of Defense prohibited-ingredient list, and a real case yielded a four-year ban. They will fail an anti-doping test.